Neuroendocrine System in HS


About this study

The purpose of this study is to focus on the interaction between stress hormones and mast cells (MCs in lesional skin of Hidradenitis Suppurativa (HS) patients. In clinical practice, psychological stress can trigger the symptoms in HS patients. Furthermore, there is increasing evidence to suggest that there is a link between chronic inflammatory skin disorders and psychiatric comorbidities even though it isdifficult to decipher the impact of underlying cutaneous inflammatory disease compared to the psychosocial impact of living with chronic illness.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Male or female, at least 18 years old.
  • Subjects with diagnosis of Hidradenitis Suppurativa (HS) and at least one active inflammatory lesion (nodule, abscess or tunnel) and has indication for deroofing or surgery.
  • Subject must be in general good health without uncontrolled significant co-morbid conditions (except for hidradenitis suppurativa) as judged by the investigator, based on medical history.
  • Has/will have undergone surgery for HS treatment at the Department of Dermatology, Mayo Clinic between September 2021 and December 31, 2022

Exclusion Criteria:

  • Individuals < 18 years old.

Eligibility last updated 9/10/21. Questions regarding updates should be directed to the study team contact.







Inclusion Criteria:

-           -          




Exclusion Criteria: 

  • Current use of any biologics, mast cell stabilizer or investigational drug within 4 weeks prior to skin sample, or 5 pharmacokinetic/pharmacodynamics half-lives, if known (whichever is longer)
  • Patients who have the comorbidities listed below:
    • Mast cell disorder
    • Active infection
    • Malignancy
    • Pregnancy
    • Major dermatitis (e.g. atopic dermatitis, psoriasis)
  • Patients whose records are incomplete


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Afsaneh Alavi, M.D.

Open for enrollment

Contact information:

Mika Takaichi M.D., Ph.D.

(507) 266-1078

More information


Publications are currently not available

Mayo Clinic Footer